Hyperforin: A potent anti-depressant natural drug

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue SUPPL 3, 2013, Pages 9-13

  Jat, Lala Ram ^a  

^a Mahatma Gandhi College of Pharmaceutical Sciences   (India)

Author keywords

Cytochrome P450; P glycoprotein; SJW; Standardized

Indexed keywords

ALPRAZOLAM; ATORVASTATIN; CAFFEINE; CHLORZOXAZONE; CYCLOSPORIN; CYTOCHROME P450; DEBRISOQUINE; DEXTROMETHORPHAN; DIGOXIN; FLUOXETINE; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; IRINOTECAN; IVABRADINE; MEPHENYTOIN; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; NEFAZODONE; NIFEDIPINE; OMEPRAZOLE; PAROXETINE; RIFAMPICIN; SERTRALINE; SIMVASTATIN; TOLBUTAMIDE; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL; WARFARIN;

ANXIETY; DEPRESSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG STRUCTURE; FATIGUE; HEADACHE; HUMAN; HYPERICUM PERFORATUM; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESTLESSNESS; REVIEW; XEROSTOMIA;

EID: 84882784322     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Gharge D, Pavan T, Sunil B, Dhabale P. Hyperforin as a natural antidepressant: an overview Journal of Pharmacy Research 2009, 2(9), 1373-1375.
2. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. British Medical Journal 2005 Mar; 330: 503-7.
3. Fava M, Alpert J, Nierenberg AA, Mischoulon D. A double-blind, randomized trial of St. John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005 Oct; 25(5): 441-7.
4. Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005 Mar; 38(2): 78-86.
5. Francesca Borrelli, and Angelo A. Izzo. AAPS Journal, Vol. 11, No. 4, December 2009.
6. Teufel-Mayer R, Gleitz J. Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2A receptors. Pharmacopsychiatry 1997 Sep; 30 Suppl 2: 113-6.
7. Calapai G, Crupi A, Firenzuoli F. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J Pharm Pharmacol 1999 Jun; 51(6): 723-8.
8. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 2005; 78: 25-33.
9. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008; 64: 935-51.
10. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004; 75: 191-7.
11. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol. 2008; 153: 1579-86.
12. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother. 1999; 33: 502.
13. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol. 2004; 44: 95-101.
14. Eich-Höchli D, Oppliger R, Golay KP, Baumann P, Eap CB. Methadone maintenance treatment and St. John's wort-a case report. Pharmacopsychiatry. 2003; 36: 35-7.
15. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002; 94: 1247-9.
16. Van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM. Possible drug-metabolism pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2000; 68: 605-12.
17. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging. 2005; 22: 525-39.
18. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002; 72: 276-87.
19. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003; 290: 1500-4.
20. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001; 70: 317-26.
21. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther. 2003; 73: 41-50.
22. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003; 74: 525-35.
23. Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol. 2008; 65: 701-7.
24. Portolés A, Terleira A, Calvo A, Martínez I, Resplandy G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol. 2006; 46: 1188-94.
25. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. St John's wort decreases the bioavailability of R-and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther. 2004; 75: 298-309.
26. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther. 1974; 16: 348-54.
27. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2004; 57: 592-9.
28. Donath F, Roots I, Langheinrich M. Interaction of St John's wort extract with phenprocoumon. Eur J Clin Pharmacol. 1999; 55: A22.
29. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther. 2001; 70: 518-24.
30. Skolnick JL, Stoler BS, Katz DB, Anderson WH. Rifampin, oral contraceptives, and pregnancy. JAMA. 1976; 236: 1382.
31. Trepanier LA. Cytochrome P450 and its role in veterinary drug interactions. Vet Clin North Am Small Anim Pract. 2006; 36: 975-85.
32. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res. 2008; 52: 755-63.
33. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci. 2000; 66: PL133-9.
34. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. 2005; 71: 331-7.
35. Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J. The influence of St John's Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol. 2004; 44: 577-81.
36. Wenk M, Todesco L, Krähenbühl S. Effect of St John's wort on the activities of YP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol. 2004; 57: 495-9.
37. Roby CA, Dryer DA, Burstein AH. St. John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol. 2001; 21: 530-2.
38. Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T. CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol. 2005; 45: 352-6.
39. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003; 74: 525-35.
40. Gordon JB. SSRIs and St John's wort: possible toxicity? Am Fam Phys. 1998; 57: 950.